Indications and outcomes of cirrhosis and acute on chronic liver failure patients undergoing liver transplantatio

Not Applicable

• Conditions: Health Condition 1: K72- Hepatic failure, not elsewhere classifiedHealth Condition 2: K744- Secondary biliary cirrhosis

• Registration Number: CTRI/2023/01/048789
• Lead Sponsor: European Foundation for the Study of Chronic Liver Failure

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Subjects with the diagnosis of liver cirrhosis

2. subjects who have been hospitalized for acute decomposition of liver cirrhosis and referred to the transplant team

3. Patients who have been informed and signed for informed consent

Exclusion Criteria

1. Acute or subacute liver failure without underlying cirrhosis

2. Patients with hepatocellular carcinoma outside Milan criteria or other active neoplasia

3. Subjects listed for transplantation other than the liver or liver-kidney transplant

4. Subjects with previous liver transplantation

5. Vulnerable population

6. Pregnant and/ or breastfeeding women

Patients who cannot provide prior informed consent

7. Patients and team not committed to providing intensive care if needed

8. Patients with relevant comorbidities that could impact the prognosis:

Subjects with very severe hepatopulmonary syndrome

subjects with severe pulmonary disease obstructive lung disease

subjects with chronic kidney disease requiring hemodialysis

subjects with severe heart disease

subjects with known infection with HIV

subjects with neurological or psychiatric disorders

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To estimate the 1-year graft and patient survival rate after liver transplant (LT) in ACLF 2/3 with patients with decompensated cirrhosis with ACLF 2 and 3Timepoint: 0,3,6,9,12 months

Secondary Outcome Measures

Name	Time	Method
To identify factors in decision-making for listing patients with severe ACLF to transplant team <br/ ><br>To compare the clinical course of patients with ACLF2/3 with decompensated cirrhosis without ACLF 2/3 <br/ ><br>To identify predictive factors of death or delisting on the waiting list for patients with ACLF 2 and 3 <br/ ><br>To identify predictive factors for death after LT <br/ ><br>To identify and compare post-LT survival rate and Quality of life in patients with ACLF 2/3 with patients with decompensated cirrhosis without ACLF 2/3Timepoint: 0,3,6,9,12 months